Further analysis of the effects of TAC on serum lipid metabolism enzyme activities showed that the model group had significantly reduced serum HL and LPL levels and significantly increased HMGCR levels, indicating the involvement of HL, LPL, and HMGCR in the development of hyperlipidemia and fatty liver (Figure 4). The gene discussed is LIPC; the disease is hyperlipidemia.